XELJANZ/XELJANZ XR [prescribing information]. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.Gastrointestinal perforations have been reported in XELJANZ clinical trials, although the role of JAK inhibition is not known. Interim Care Rx offer does not require, nor will be made contingent on, purchase requirements of any kind. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.Gastrointestinal perforations have been reported in XELJANZ clinical trials, although the role of JAK inhibition is not known. Additional eligibility criteria may apply. XELJANZ/XELJANZ XR [prescribing information]. Lee EB, Fleischmann R, Hall S, et al; for the ORAL Start Investigators. for a period of time if needed because of changes in these blood test results.You may also have changes in other laboratory tests, such as your blood cholesterol levels. Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification. Update immunizations in agreement with current immunization guidelines prior to initiating XELJANZ/XELJANZ XR therapy.Caution should be used when administering XELJANZ XR to patients with pre-existing severe gastrointestinal narrowing. treat:It is not known if XELJANZ/XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.XELJANZ/XELJANZ XR is not recommended for people with severe liver problems.You should not start taking XELJANZ/XELJANZ XR if you have any kind of infection unless your healthcare New York, NY: Pfizer Inc; July 2019.Mease P, Hall S, FitzGerald O, et al. Offer is not valid for cash paying patients. New York, NY: Pfizer Inc; July 2019.Lamba M, Wang R, Fletcher T, Alvey C, Kushner J VI, Stock TC. XELJANZ/XELJANZ XR can make you more likely to get infections or make worse any infection that you If you are a carrier of the Hepatitis B or C virus (viruses that affect the Terms and Conditions apply. Invasive fungal infections, including cryptococcosis and pneumocystosis. Immune regulation in psoriasis and psoriatic arthritis—recent developments. Interim Care Rx offer does not require, nor will be made contingent on, purchase requirements of any kind. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. Skip to main content Back to top . New York, NY: Pfizer Inc; July 2019.XELJANZ/XELJANZ XR [prescribing information]. van der Heijde D, Tanaka Y, Fleischmann R, et al; and the ORAL Scan Investigators. very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes You are responsible for reporting use of the Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required. Lee EB, Fleischmann R, Hall S, et al; for the ORAL Start Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start XELJANZ/XELJANZ XR, XELJANZ/XELJANZ XR [prescribing information]. Your healthcare provider may stop your XELJANZ/XELJANZ XR treatment You are encouraged to report adverse events related to Pfizer products by calling If your doctor has prescribed XELJANZ and you need help paying for it, This site is intended only for U.S. residents. Immune regulation in psoriasis and psoriatic arthritis—recent developments. In the UC population, treatment with XELJANZ 10 mg twice daily was associated with greater risk of NMSC. Opportunistic herpes zoster infections (including meningoencephalitis, ophthalmologic, and disseminated cutaneous) were seen in patients who were treated with XELJANZ 10 mg twice daily.Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with XELJANZ/XELJANZ XR, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.Caution is also recommended in patients with a history of chronic lung disease, or in those who develop interstitial lung disease, as they may be more prone to infection.Consider the risks and benefits of XELJANZ/XELJANZ XR treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing XELJANZ/XELJANZ XR in patients who develop a malignancy.Malignancies (including solid cancers and lymphomas) were observed more often in patients treated with XELJANZ 10 mg twice daily dosing in the UC long-term extension study.Other malignancies were observed in clinical studies and the post-marketing setting including, but not limited to, lung cancer, breast cancer, melanoma, prostate cancer, and pancreatic cancer. van Vollenhoven RF, Fleischmann R, Cohen S, et al; for the ORAL Standard Investigators.